北京若生智能科技有限公司
Drug Database
TR

travoprost + timolol (TTFC, Alcon / TTFC, Alcon)

✓ Approved

Novartis AG · ADRB1 · 小分子

什么是 travoprost + timolol？

travoprost + timolol 是一种小分子，由Novartis AG研发。该药已获批，用于治疗相关适应症，给药途径：Others。

药物档案

商品名TTFC, Alcon, TTFC, Alcon
公司Novartis AG
药物类别小分子
分子靶点ADRB1, ADRB2, PTGFR
给药途径Others
状态Approved
来源： ClinicalTrials.gov, Novartis AG

作用机制

分子靶点

travoprost + timolol 作用于 3 个分子靶点：

ADRB1adrenoceptor beta 1 (B1AR, RHR)
ADRB2adrenoceptor beta 2 (ADRBR, B2AR)
PTGFRprostaglandin F receptor (FP)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

travoprost + timolol 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Eye disordersGlaucoma✓ Approved

相关研究文献

PubMedClinical ophthalmology (Auckland, N.Z.)2026-09-10

Intraoperative Quantification of Incision-Site Descemet Membrane Detachment During Phacoemulsification: A Paired-Eye Comparison of Longitudinal and Torsional Ultrasound.

Bulir Petr P, Studeny Pavel P

To quantify the extent of clinically non-significant Descemet membrane detachment (DMD) at the clear corneal incision (CCI) during phacoemulsification and to compare its extent between longitudinal and torsional ultrasound modulation as a morphological marker of local tissue-instrument interaction. In this prospective contralateral-eye comparative randomized study, 14 patients (28 eyes) undergoing bilateral cataract surgery were included. One eye received longitudinal and the fellow eye torsional ultrasound (Constellation system, Alcon). DMD was assessed intraoperatively using microscope video recordings under red reflex illumination. Still images were analyzed, and DMD area (mm2) at the internal wound was measured. Correlations with cumulative dissipated energy (CDE) was evaluated. Incision-site DMD was detected in all analyzed cases (100%) using intraoperative red reflex-based visualization. Mean DMD area was 1.33 ± 0.43 mm2 (longitudinal) and 2.37 ± 0.67 mm2 (torsional), with a mean difference of 1.04 mm2 ± 0.74 mm2 (95% CI, 0.60-1.48). The paired analysis demonstrated a highly significant difference (p < 0.001). No correlation was found between DMD extent and CDE. Clinically non-significant incision-site DMD appears to be a frequent intraoperative morphological phenomenon during phacoemulsification when assessed using sensitive visualization techniques. Torsional ultrasound was associated with a significantly greater DMD extent than longitudinal modulation. Rather than indicating greater clinical damage, DMD area may serve as a sensitive quantitative morphological marker of local tissue-instrument interaction at the corneal incision. Its potential value therefore lies primarily in the comparative evaluation and future refinement of phacoemulsification technologies, while the clinical significance of these subtle morphological differences remains to be established.

PMID 42719804
阅读全文 →
PubMedJournal of cataract and refractive surgery2026-09-09

Comparison of the functional defocus curve between eyes with diffractive multifocal intraocular lenses and age-stratified phakic eyes.

Hayashi Ken K, Yoshida Motoaki M, Hayashi Shunsuke S, Manabe Shin-Ichi SI

To compare the functional defocus curve between eyes with diffractive multifocal intraocular lenses (DMIOLs) and age-stratified phakic eyes with clear lenses. Hayashi Eye Hospital, Fukuoka, Japan. Prospective comparative study. Eighty-five eyes of 85 patients aged ≥60 years with DMIOLs (Alcon PanOptix™, n=40; Johnson & Johnson Odyssey™, n=45) and 380 phakic eyes of patients in their 30s, 40s, 50s, and 60s were enrolled. Distance-corrected visual acuity (VA) at various simulated distances was measured at 3 months postoperatively using an all-distance vision tester and compared between groups. Mean distance-corrected VA at most distances was significantly worse in the DMIOL groups than in phakic patients in their 30s (P≤.002). Compared with phakic patients in their 40s, the PanOptix group had significantly better distance-corrected near VA (DCNVA) at 0.3m and intermediate VA (DCIVA) at 0.5m, but worse DCIVA at 1.0m, whereas the Odyssey group had better DCNVA but worse DCIVA at 0.7 and 1.0m (P≤.002). Mean DCNVA and DCIVAs at 0.5, and 0.7m were significantly better in the DMIOL groups than in phakic patients in their 50s and 60s (P<.001), except for DCIVA at 0.7m in patients in their 50s. The functional defocus curve in eyes with DMIOLs was comparable to that in phakic eyes of patients in their 40s and superior to that in phakic eyes of patients in their 50s and 60s, indicating that DMIOLs may restore the functional range of vision to that of phakic patients in their 40s.

PMID 42715253
阅读全文 →
PubMedJournal of refractive surgery (Thorofare, N.J. : 1995)2026-09-09

Viscoelastic-Assisted Patient Interface Docking: A Technical Optimization in LenSx Femtosecond Laser-Assisted Cataract Surgery.

Cao Danmin D, Luo Wenjing W, Li Juan J, Peng Tingting T et al.

To evaluate the efficacy of viscoelastic-assisted patient interface docking in LenSx (Alcon Laboratories, Inc) femtosecond laser-assisted cataract surgery (FLACS). This was a randomized controlled trial. Patients undergoing FLACS from January to August 2025 at Aier Eye Hospital of Wuhan University were randomized via a random number table to receive balanced salt solution (BSS) or visoeleastic as the patient interface docking medium. The primary outcome was docking efficiency, measured by one-time docking success rate, the number of docking attempts, and mean docking time. Secondary outcomes included surgical safety (subconjunctival hemorrhage, capsulotomy completeness/tear rate), laser treatment duration (anterior capsulotomy time, nucleus pretreatment time, total laser emission time), and patient comfort (post-laser pain sensation). A total of 100 patients were enrolled, 50 in each group. Suction loss occurred in 7 patients (14%) in the BSS group and 1 patient (2%) in the viscoelastic group; the one-time docking success rate was significantly higher in the viscoelastic group (98%) than in the BSS group (86%) (chi-square = 3.93, P < .05). The viscoelastic group also had fewer mean docking attempts (1.02 ± 0.14) than the BSS group (1.16 ± 0.42), showing a significant difference (t = 2.23, P < .05). The viscoelastic group exhibited significantly shorter mean docking time (44.66 ± 4.47 seconds) compared to the BSS group (48.62 ± 3.11 seconds) (t = 2.17, P < .05). No significant differences were observed between the groups in subconjunctival hemorrhage, capsulotomy completeness/tear rate, anterior capsulotomy time, nucleus pretreatment time, total femtosecond laser emission time, or patient-reported pain sensation (all P > .05). Viscoelastic-assisted patient interface docking in FLACS effectively elevates one-time docking success rate, reduces docking attempts, and shortens docking time.

PMID 42715027
阅读全文 →
PubMed[Zhonghua yan ke za zhi] Chinese journal of ophthalmology2026-09-07

[Tafluprost/timolol fixed-dose combination versus tafluprost monotherapy for open-angle glaucoma and ocular hypertension: a multicenter, randomized, double-blind, parallel-group trial].

Wang K D KD, Zhao P P, Wu L L LL, Zhang T H TH et al.

Objective: To evaluate the efficacy and safety of a preservative-free tafluprost/timolol maleate fixed-dose combination compared with preservative-free tafluprost monotherapy in Chinese patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods: This was a multicenter, randomized, double-blind, parallel-controlled clinical trial conducted across 25 centers, including the Eye & ENT Hospital of Fudan University, from January 2019 to November 2022. Patients diagnosed with OAG or OHT who required enhanced intraocular pressure (IOP) reduction after a 4-week washout period were enrolled. Participants were randomized 1∶1 to receive either tafluprost/timolol or tafluprost once daily for 3 months. The primary endpoint was the change from baseline in mean diurnal IOP (the average of measurements at 8:00, 10:00, and 16:00) at Month 3. Secondary endpoints included IOP changes at individual time points and the proportion of responders achieving predefined IOP reduction thresholds. Safety was assessed via the incidence of adverse events (AEs). Analysis of covariance (ANCOVA) using the Markov Chain Monte Carlo (MCMC) method was employed for the primary endpoint; superiority was established if the upper limit of the 95% confidence interval (CI) was<0 mmHg (1 mmHg=0.133 kPa). Continuous variables in secondary endpoints were compared using ANCOVA, and responder rates were analyzed using Fisher's exact test. Results: A total of 219 patients were enrolled (tafluprost/timolol group: n=110; tafluprost group: n=109). The primary efficacy analysis set included 215 patients (tafluprost/timolol: n=107; tafluprost: n=108). Baseline characteristics were well-balanced between the two groups. The majority of patients were male [127 (59.1%)] with a mean age of (44.80±15.71) years at screening. At Month 3, the mean diurnal IOP reduction from baseline was (6.56±3.44) mmHg in the tafluprost/timolol group and (5.36±2.94) mmHg in the tafluprost group. After adjusting for baseline IOP, the between-group difference was -1.312 mmHg (95%CI: -2.010 to -0.696); as the upper limit was<0 mmHg, tafluprost/timolol demonstrated superior IOP-lowering efficacy to tafluprost. Responder rates for IOP reductions of≥15%,≥25%, and≥30% were significantly higher in the tafluprost/timolol group (P=0.016, 0.028, and 0.032, respectively). The incidence of ocular AEs was 20.0% (22/110) in the tafluprost/timolol group and 26.6% (29/109) in the tafluprost group. The most common AE was conjunctival hyperemia, occurring in 2.7% (3/110) and 8.3% (9/109) of the groups, respectively. Conclusion: Compared with preservative-free tafluprost monotherapy, the tafluprost/timolol combination provides significantly greater IOP reduction in patients with OAG and OHT, while maintaining a favorable safety profile.

PMID 42706141
阅读全文 →
PubMedPediatric annals2026-09-03

Recognition and Management of Ulcerative Infantile Hemangioma: Risk Factors, Diagnosis, and Prognosis.

Veronica Elvina E, Cai Qiushuang Q, Shen Qin Q, Jiang Yijing Y et al.

Infantile hemangioma (IH) is a benign tumor that appears in the first year of life and typically involutes within 3 to 4 years. Ulcerative IH, the most common complication, poses a significant burden to patients. Early referral of high-risk cases reduces morbidity. Current literature on risk factors and prognosis is limited. Segmental and mixed IH in urogenital, head, neck, and lip areas show higher ulceration risk. Diagnosis is typically clinical; histopathology is rarely performed. Atypical cases require positive glucose transporter-1 immunohistochemistry. Larger lesions, delayed intervention, and bacterial infection worsen prognosis, prolong healing, and increase recurrence. Condition-dependent treatments, including oral propranolol (starting at 1 mg/kg or less daily, maintenance at 2 to 3 mg/kg daily), timolol prophylaxis, and wound management care combined with laser therapy, shorten therapy duration and minimize recurrence. Empiric antibiotics are indicated for infected ulcerative IH. Surgery is indicated for life-threatening cases (eg, chest wall hemangiomas requiring transfusion or airway obstruction) and high-morbidity cases (eg, lip lesions affecting speech or periorbital lesions impairing vision). The Infantile Hemangioma Referral Score helps clinicians identify high-risk patients who require prompt referral, thereby preventing delayed treatment.

PMID 42692987
阅读全文 →
PubMedAdvances in therapy2026-09-01

Travoprost Intracameral Implant as a Standalone Procedure or Combined with Minimally Invasive Glaucoma Surgery (MIGS).

Yadgarov Arkadiy A

The primary objective of this study was to report real-world outcomes of the travoprost intracameral implant (iDose TR) as standalone surgery or combined with minimally invasive glaucoma surgery (MIGS). The secondary objective was to compare efficacy across subgroups stratified by surgical category, severity, and race/ethnicity. This was a retrospective nonrandomized single-center consecutive case series of iDose TR implantations, with or without MIGS. Inclusion criteria were primary open-angle glaucoma, mild-to-severe stage, and minimum 3 months' follow-up. Eyes with visually significant cataract undergoing combined surgery also underwent concomitant phacoemulsification. Efficacy endpoints were mean and proportional analyses of IOP and medication burden (at baseline vs 3 months). The study included 85 eyes. iDose TR was a standalone procedure in 40 eyes (47.1%) and combined with MIGS in 45 eyes (52.9%): iDose + iStent infinite (n = 22), iDose + iStent infinite + phacoemulsification (n = 16), and iDose + other MIGS ± phacoemulsification (n = 7). IOP and medication burden reduced significantly from 17.2 ± 5.1 and 1.9 ± 1.1 mmHg preoperatively to 14.5 ± 4.3 and 0.9 ± 0.9 mmHg at 3 months in all eyes (p < 0.001). Subgroup analyses revealed significant reductions in IOP and medication burden across all subgroups with no significant between-subgroup differences, except in the surgical category analysis which showed statistically significantly greater medication reduction after combined procedures than standalone procedures. There were no intraoperative complications. Postoperatively, IOP elevation (n = 1) and branch retinal vein occlusion (n = 1) were observed. No secondary glaucoma interventions were required. iDose TR achieved significant and safe IOP and medication reduction when performed as standalone surgery or combined with trabecular outflow-based MIGS with or without concomitant phacoemulsification. Greater medication-reducing effect was observed following combined iDose TR + MIGS surgery than with standalone iDose TR implantation. Study limitations include the short follow-up, nonrandomized design, and small, unmatched subgroups; further randomized studies with large, matched cohorts will be helpful to validate these findings.

PMID 42678487
阅读全文 →

注册免费账户还可查看另外 7335 篇文献

免费注册查看全部文献 →

了解更多travoprost + timolol